Incyte gains after data presentations

Incyte (NASDAQ:INCY) gained $1.92 (20%) to $11.39 on Tuesday after reporting data from five clinical trials at the JPMorgan Healthcare Conference in San Francisco. Incyte presented data from three trials of INCB18424, including Phase IIa data on the Janus-associated kinase (JAK) inhibitor to treat rheumatoid arthritis (RA) and psoriasis, as well as Phase Ib/IIa data to treat myelofibrosis. ...